Cibus Q2 net loss narrows to $26.6M; cash runway into Q2 2026; Rice trait commercialization on track

Cibus, Inc.

2025-Q2 EPS reported -$1.88 revenue$1,967,000

Net loss $26.6M ($0.61 per share) vs $28.5M ($1.14) YoY; R&D $12.2M, SG&A $6.6M, both down on cost cuts.
Cash $36.5M at June 30; raised $27.5M gross from June offering; expects funding into Q2 2026.
Streamlining targets annual cash usage ~$30M by 2026; focused on Rice herbicide tolerance and partner-funded programs.
Rice HT1/HT3 traits on track for Latin America launch 2027, US 2028; signed collaboration with Colombia's Semillano; delivered HT3 lines to US customer.
Sustainable ingredients program on track for nominal 2025 revenues; regulatory wins: Ecuador cleared HT1/HT3 as non-GMO, USDA deregulated HT2 canola.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.